TENIDAP — Competitive Intelligence Brief

TENIDAP (TENIDAP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tenidap. Area: Immunology.

phase 2 tenidap Prostaglandin G/H synthase 1 Immunology Small molecule

Target snapshot

TENIDAP (TENIDAP). TENIDAP works by inhibiting the enzyme Prostaglandin G/H synthase 1, which plays a key role in the production of inflammatory mediators.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TENIDAP TARGET	TENIDAP		phase 2	tenidap	Prostaglandin G/H synthase 1
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	marketed	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01
DEXIBUPROFEN	DEXIBUPROFEN		marketed	dexibuprofen	Prostaglandin G/H synthase 1	1994-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tenidap class)

1. · 1 drug in this class